BioMark Diagnostics Inc.
BUX
Rank in Stocks
#26617
BioMark Diagnostics Inc. is an oncology specialist, developing advanced... BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
Share Price
$0.34495034
Last synced: 2026-10-16
Market Cap
$36.73M
Change (1 day)
-4.08%
Change (1 year)
53.78%
Country
CA
Trade BioMark Diagnostics Inc. (BUX)
Category
Healthcare
P/S ratio for BioMark Diagnostics Inc. (BUX)
P/S ratio as of 2026 TTM: 0
According to BioMark Diagnostics Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for BioMark Diagnostics Inc. from 2026 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 5.37 | - |
US
|
|
| 6.29 | - |
US
|
|
| 21.02 | - |
US
|
|
| - | - |
CN
|
|
| 6.67 | - |
US
|
